BioRestorative Therapies Faces Delisting, Going Concern Doubt Amid Highly Dilutive Capital Raises
BRTX sits 56% above its 52-week low of $0.19 on light trading volume (0.2× avg).
Summary
BioRestorative Therapies' annual report reveals substantial doubt about its ability to continue as a going concern, a Nasdaq delisting notice, and significant dilutive capital raises, despite some clinical trial progress.
Key Events · Legal and Risk Events · BRTX
-
Substantial Doubt About Going Concern
The company's financial statements include an explanatory paragraph from its independent registered public accounting firm expressing substantial doubt about its ability to continue as a going concern for at least the next twelve months, citing a $14.2 million net loss and $10.8 million negative cash flow from operations for 2025, and a $0.6 million working capital deficit.
-
Nasdaq Delisting Notice Received
On March 26, 2026, the company received a notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement for 30 consecutive business days. It has an initial 180-calendar-day period, until September 22, 2026, to regain compliance.
-
Highly Dilutive Public Offering Completed
In February 2026, the company completed a public offering, raising $5.0 million in gross proceeds by issuing 12,560,715 shares of common stock, 1,725,000 pre-funded warrants (all exercised by March 13, 2026), and 14,285,715 common stock warrants. The common stock warrants have an exercise price of $0.35 per share, and placement agent warrants for 1,000,000 shares at $0.4375.
-
Material Weaknesses in Internal Controls
Management identified material weaknesses in the design and operation of its internal control over financial reporting as of December 31, 2025, related to adherence to formal policies, risk assessment procedures, and effective controls for financial reporting.
Analysis · BRTX · Industrial Applications And Services
The 10-K filing highlights severe financial challenges for BioRestorative Therapies, including an auditor's opinion raising substantial doubt about its ability to continue as a going concern. The company also received a Nasdaq delisting notice for failing to meet the minimum bid price requirement, initiating a 180-day compliance period. To address its liquidity needs, the company undertook highly dilutive offerings, including a $5.0 million public offering in February 2026 that involved issuing common stock and warrants, significantly increasing the outstanding share count. These capital raises, while providing some short-term funding, come at a substantial cost to existing shareholders. The company also reported a widening net loss and negative cash flow from operations for 2025, alongside identified material weaknesses in internal controls. While there are positive updates on clinical trial enrollment and FDA discussions for its lead candidate BRTX-100, these developments are overshadowed by the immediate and existential financial and compliance risks.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 40.2% of the 326 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.33%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BRTX was trading at $0.30 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.4M. The 52-week trading range was $0.19 to $2.05. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.